TRMS.....EWH
jim.
TRMS.
last night
i read press releases from TRMS
regarding their T-20, and i was fortunate
enough to trade it today successfully.
but, its ascension to 13 status carries with it
the unmistakable imprint of a meteoric rise...
having closed monday at 4 7/8, it opened today
at 8, reached as high as 10 3/4, and finally closed at 9.
for what its worth.... also, see article below*
EWH
are you very familiar with WEBs?
( web equity baskets...)
thanks,
randy
ps
FOUR published a solid annual report & appears to be holding its own.
Trimeris Announces Publication of Phase I/II Clinical Trial Results of T-20, A Novel HIV Drug
DURHAM, N.C.--(BUSINESS WIRE)--Nov. 3, 1998--
First in New Class of Drugs Shows Potency and Safety
Trimeris, Inc. (NASDAQ: TRMS) announced today publication of Phase I/II clinical trial results of T-20 in the November issue of Nature Medicine. As a fusion inhibitor, T-20 is the first of a new class of anti-HIV drugs that block the entry of the virus into cells. T-20 produces a potent antiviral effect even in HIV-infected subjects who have been treated with other anti-viral agents. The article was a collaboration among the University of Alabama at Birmingham, Duke University, and Trimeris, Inc. The authors note that the short-term potency of T-20, when given alone, reduces viral load at a rate comparable to current 3 and 4 drug combination regimens of reverse transcriptase inhibitors and protease inhibitors.
In the Phase I/II clinical trial, T-20 was administered for fourteen days to 16 HIV infected adults, including some with prior antiretroviral treatment. "T-20 was safely dosed in all patients with no serious toxicities. We were pleased to find that patients in the highest dose group experienced profound reductions of viral load even though T-20 was the only anti-HIV drug they were receiving during the study period," stated Dr. Michael Kilby the principal investigator for the study at UAB.
"The results of the first T-20 clinical trial are important as we look forward to the future treatment of HIV/AIDS," stated Dr. Joseph Eron, a leading HIV researcher from the University of North Carolina at Chapel Hill. "There is an increasing pool of HIV infected patients who are beginning to become non-responsive to currently available treatments. As one looks at the drug development pipeline, T-20 is the only drug in Phase II clinical trials that attacks HIV by a different mechanism of action. This means that T-20 should be effective against the emerging multiple drug resistant virus that is increasingly difficult to treat."
The Company's current Phase II clinical trial, TRI-003, is designed to define the optimal dose(s), compare the effectiveness of continuous infusion versus intermittent injection, and provide additional data regarding the effect of T-20 on viral load. Results from TRI-003 are expected to be reported in early 1999. These data will provide a basis for initiating pivotal clinical trials during 1999. |
